Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Ferring Pharmaceuticals and Theralase ® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical ...

Following an intensive period of consultation, Relmada has received formal regulatory guidance from the FDA for NDV-01 in non-muscle invasive bladder cancer (NMIBC). The agency has agreed to support ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...

TAR-200 achieved an 82% tumor elimination rate in high-risk non-muscle-invasive bladder cancer patients resistant to previous treatments. The device releases gemcitabine into the bladder over three ...

Fred Hutch Cancer Center researchers are seeking better ways to prevent, detect and treat bladder cancer. We are also working to better understand the factors that affect each person’s risk for this ...

Working with a physical therapist who specializes in pelvic floor disorders could offer better control for some patients ...